Ascelia Pharma: A timely FDA submission with an extended cash runway - Redeye

Ascelia has now submitted Orviglance to the FDA. The next step is to start the initial filing review process with an FDA confirmation within 74 days from submission.

Länk till analysen i sin helhet: https://www.redeye.se/research/1126475/ascelia-pharma-a-timely-fda-submission-with-an-extended-cash-runway?utm_source=finwire&utm_medium=RSS